Literature DB >> 10100300

Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: concepts and perspectives.

H Derendorf1, B Meibohm.   

Abstract

Pharmacokinetic/pharmacodynamic (PK/PD)-modeling links dose-concentration relationships (PK) and concentration-effect relationships (PD), thereby facilitating the description and prediction of the time course of drug effects resulting from a certain dosing regimen. PK/PD-modeling approaches can basically be distinguished by four major attributes. The first characterizes the link between measured drug concentration and the response system, direct link versus indirect link. The second considers how the response system relates effect site concentration to the observed outcome, direct versus indirect response. The third regards what clinically or experimentally assessed information is used to establish the link between concentration and effect, hard link versus soft link. And the fourth considers the time dependency of pharmacodynamic model parameters, distinguishing between time-variant versus time-invariant. Application of PK/PD-modeling concepts has been identified as potentially beneficial in all phases of preclinical and clinical drug development. Although today predominantly limited to research, broader application of PK/PD-concepts in clinical therapy will provide a more rational basis for patient-specific dosage individualization and may thus guide applied pharmacotherapy to a higher level of performance.

Entities:  

Mesh:

Year:  1999        PMID: 10100300     DOI: 10.1023/a:1011907920641

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  61 in total

1.  Pharmacodynamic modeling of furosemide tolerance after multiple intravenous administration.

Authors:  M Wakelkamp; G Alván; J Gabrielsson; G Paintaud
Journal:  Clin Pharmacol Ther       Date:  1996-07       Impact factor: 6.875

Review 2.  Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling.

Authors:  B Meibohm; H Derendorf
Journal:  Int J Clin Pharmacol Ther       Date:  1997-10       Impact factor: 1.366

3.  Efficacy measures: surrogates or clinical outcomes?

Authors:  J W Blue; W A Colburn
Journal:  J Clin Pharmacol       Date:  1996-09       Impact factor: 3.126

4.  An evaluation of the integration of pharmacokinetic and pharmacodynamic principles in clinical drug development. Experience within Hoffmann La Roche.

Authors:  B G Reigner; P E Williams; I H Patel; J L Steimer; C Peck; P van Brummelen
Journal:  Clin Pharmacokinet       Date:  1997-08       Impact factor: 6.447

5.  Population pharmacokinetic-pharmacodynamic analysis of fluindione in patients.

Authors:  F Mentré; F Pousset; E Comets; B Plaud; B Diquet; G Montalescot; A Ankri; A Mallet; P Lechat
Journal:  Clin Pharmacol Ther       Date:  1998-01       Impact factor: 6.875

6.  Pharmacokinetics of digoxin: relationship between response intensity and predicted compartmental drug levels in man.

Authors:  W G Kramer; A J Kolibash; R P Lewis; M S Bathala; J A Visconti; R H Reuning
Journal:  J Pharmacokinet Biopharm       Date:  1979-02

7.  Pharmacokinetic-pharmacodynamic analysis of unbound disopyramide directly measured in serial plasma samples in man.

Authors:  M Thibonnier; N H Holford; R A Upton; C D Blume; R L Williams
Journal:  J Pharmacokinet Biopharm       Date:  1984-12

Review 8.  Pharmacokinetic and pharmacodynamic modeling in vivo.

Authors:  N H Holford; L B Sheiner
Journal:  Crit Rev Bioeng       Date:  1981

9.  Third-generation model for corticosteroid pharmacodynamics: roles of glucocorticoid receptor mRNA and tyrosine aminotransferase mRNA in rat liver.

Authors:  Z X Xu; Y N Sun; D C DuBois; R R Almon; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1995-04

10.  Diclofenac plasma protein binding: PK-PD modelling in cardiac patients submitted to cardiopulmonary bypass.

Authors:  J O Auler Júnior; E B Espada; E Crivelli; T B Quintavalle; A Kurata; N A Stolf; A M Issy; O E Paschoa; M Danhof; D D Breimer; D A Chamone; S R Santos
Journal:  Braz J Med Biol Res       Date:  1997-03       Impact factor: 2.590

View more
  68 in total

Review 1.  Nonlinear dynamics and chaos theory: concepts and applications relevant to pharmacodynamics.

Authors:  A Dokoumetzidis; A Iliadis; P Macheras
Journal:  Pharm Res       Date:  2001-04       Impact factor: 4.200

Review 2.  Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC.

Authors:  Markus Mueller; Amparo de la Peña; Hartmut Derendorf
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

Review 3.  Pharmacokinetic-pharmacodynamic guided trial design in oncology.

Authors:  Ch van Kesteren; R A A Mathôt; J H Beijnen; J H M Schellens
Journal:  Invest New Drugs       Date:  2003-05       Impact factor: 3.850

Review 4.  Biomarkers, validation and pharmacokinetic-pharmacodynamic modelling.

Authors:  Wayne A Colburn; Jean W Lee
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 5.  Role of modelling and simulation: a European regulatory perspective.

Authors:  Siv Jönsson; Anja Henningsson; Monica Edholm; Tomas Salmonson
Journal:  Clin Pharmacokinet       Date:  2012-02-01       Impact factor: 6.447

6.  Pharmacodynamics-mediated drug disposition (PDMDD) and precursor pool lifespan model for single dose of romiplostim in healthy subjects.

Authors:  Yow-Ming C Wang; Wojciech Krzyzanski; Sameer Doshi; Jim J Xiao; Juan Jose Pérez-Ruixo; Andrew T Chow
Journal:  AAPS J       Date:  2010-10-21       Impact factor: 4.009

Review 7.  Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action.

Authors:  Georges Vauquelin; Steven J Charlton
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

8.  Prediction of repeat-dose occupancy from single-dose data: characterisation of the relationship between plasma pharmacokinetics and brain target occupancy.

Authors:  Sergio Abanades; Jasper van der Aart; Julien A R Barletta; Carmine Marzano; Graham E Searle; Cristian A Salinas; Javaad J Ahmad; Richard R Reiley; Sabina Pampols-Maso; Stefano Zamuner; Vincent J Cunningham; Eugenii A Rabiner; Marc A Laruelle; Roger N Gunn
Journal:  J Cereb Blood Flow Metab       Date:  2010-10-13       Impact factor: 6.200

9.  Theoretical basis for the identification of allelic variants that encode drug efficacy and toxicity.

Authors:  Min Lin; Rongling Wu
Journal:  Genetics       Date:  2005-03-31       Impact factor: 4.562

10.  Pharmacokinetic and pharmacodynamic of irbesartan in renal hypertensive dogs under non-steady-state and steady-state conditions.

Authors:  Xiao-Hui Huang; Fu-Rong Qiu; Hai-Tang Xie; Jun Li
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2005 Jan-Jun       Impact factor: 2.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.